上海金畔生物科技正规代理Trilink产品，zui近市场出现Trilink的假货，为了您的实验安全请选择正牌代理。 :
TriLink BioTechnologies——高品质常规/特殊核苷酸产品
TriLink BioTechnologies公司是世界的核酸修饰技术领域的，成立于1996年，总部设在San Diego，California。TriLink公司致力于高品质核酸修饰产品的研发和生产，提供包括核苷酸、常规及核苷三磷酸特殊修饰的寡核苷酸定制（oligonucleotides），m RNA合成，CleanAmp?PCR产品，phosphoramidites和其他小分子在内的众多产品。近二十年来，TriLink一直是诊断和OEM市场核酸产品供应的行业，产品应用于基因治疗，核苷类化疗，寡核苷酸治疗和诊断领域。此外，TriLink还可提供特殊核苷酸、m RNA定制，合同研究服务和ISO/ QSR标准的cGMP生产设施。TriLink完善的产品及研发服务解决方案有助于推动药物发现和生物医学研究。
经过18年的发展， TriLink已经成为高品质RNA合成领域的，为广大科研工作者提供的mRNA及长链RNA（长可达几个Kb），并且定制修饰。同时我们也提供成品mRNA产品，包括报告基因及 mRNA表达因子。
Antigen mRNA for Vaccines and Immunotherapy
mRNA offers several advantages over traditional plasmid and viral-based approaches:
- mRNA boasts a superior safety profile. As a transient carrier of genetic information, it is metabolized naturally and poses little to no risk of genomic integration. Additionally, no inactivated viruses or pathogens are needed.
- mRNA serves the dual purpose of expressing the desired antigen as well as acting as an adjuvant.
- mRNA triggers a more diverse immune response. Because the mRNA encoded epitopes are intracellular, they are recognized by the immune system in an MHC class-independent manner.
- mRNA can more readily transfect difficult-to-transfect cell types because it functions in the cytoplasm. DNA vaccines can be limited by lack of access to the nucleus.
- mRNA manufacturing is easily scalable. Because mRNA transcription is carried out compley in vitro, to hundreds of millions of vaccine doses with a lead time of as little as a few weeks. This allows for rapid deployment of a new antigen during pandemics.
- mRNA is easily customizable. The ease of manufacturing makes it a viable option for personalized treatments.
产品如下:
| 货号 | 品名 | 规格 | 价格 | 品牌 |
| Antigen mRNA | ||||
| L-7610 | CleanCap™ OVA mRNA | 20 μg | 1700 | TriLink BioTechnologies |
| L-7610 | CleanCap™ OVA mRNA | 100 μg | 4080 | TriLink BioTechnologies |
| L-7610 | CleanCap™ OVA mRNA | 1 mg | 21420 | TriLink BioTechnologies |
| L-7610 | CleanCap™ OVA mRNA | 5 mg (5 x 1 mg) | 75990 | TriLink BioTechnologies |
| L-7210 | CleanCap™ OVA mRNA (5moU) | 20 µgrams | 2125 | TriLink BioTechnologies |
| L-7210 | CleanCap™ OVA mRNA (5moU) | 100 µgrams | 5015 | TriLink BioTechnologies |
| L-7210 | CleanCap™ OVA mRNA (5moU) | 1 mg | 26775 | TriLink BioTechnologies |
| L-7210 | CleanCap™ OVA mRNA (5moU) | 5 mg (5 x 1 mg) | 96050 | TriLink BioTechnologies |
L-7210
CleanCap™ OVA mRNA (5moU)
CleanCap™ Ovalbumin mRNA (5-methoxyuridine)
mRNA Length: 1,437 nucleotides
Concentration: 1.0 mg/mL
Buffer: 1 mM Sodium Citrate, pH 6.4
Identity & Purity:
Agarose Gel Mobility; Pass
Concentration ± 5%; Pass
Product Insert
SDS
Ovalbumin (OVA) is a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.
This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
TriLink offers both unmodified and 5-methoxyuridine modified OVA mRNA. Exogenous unmodified mRNA activates the innate immune system and production of cytokines, which will influence the overall induced immune response. mRNA modified with 5-methoxyuridine reduces this effect.
Certificate(s) of Analysis
TD-OB06A
L-7210 is a replacement for L-6128,
Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.
L-7610
CleanCap™ OVA mRNA
CleanCap™ Ovalbumin mRNA
mRNA Length: 1,437 nucleotides
Concentration: 1.0 mg/mL
Buffer: 1 mM Sodium Citrate, pH 6.4
Identity & Purity:
Agarose Gel Mobility; Pass
Concentration ± 5%; Pass
Product Insert
SDS
Ovalbumin (OVA) is a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.
This mRNA is capped using CleanCap™, TriLink’s proprietary co-transcriptional capping method,
which results in the naturally occurring Cap 1 structure with high capping efficiency. It is polyadenylated and optimized for mammalian systems. It mimics a fully processed mature mRNA.
TriLink offers both unmodified and 5-methoxyuridine modified OVA mRNA. Exogenous unmodified mRNA activates the innate immune system and production of cytokines, which will influence the overall induced immune response. mRNA modified with 5-methoxyuridine reduces this effect.
Certificate(s) of Analysis
TD-OB07A
L-7610 is a replacement for L-6328.
Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.